Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Inclusion Criteria: * Pts have confirmed diagnosis of recurrent/progressive WHO gr III \& IV MG * Age \>18 rs * Interval of \>4 wks since prior surgery * Interval of \>4 wks since prior XRT/chemo, unless there is unequivocal evidence of progressive disease \& pts have recovered from all anticipated toxicity of most recent therapy; * Karnofsky performance status score \>60 * Hematocrit \>29 percent, ANC \>1,500 cells/microliter, platelets \>100,000 cells/microliter * Serum creatinine \<1.5 mg/dl, BUN \<25 mg/dl, serum SGOT \& bilirubin \<1.5 x ULN * For pts on corticosteroids, they have been on astable dose for 1wk prior to entry * Signed informed consent approved by IRB prior to pt entry * If sexually active, pts must agree to take contraceptive measures for duration of treatments. Exclusion Criteria: * Prior therapy w either bevacizumab/etoposide * \>3 prior recurrences * Pregnancy/breast feeding * Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil * Evidence of CNS hemorrhage on baseline MRI on CT scan * Pts who require therapeutic anti-coagulation * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state * Pts w another primary malignancy that has required treatment \<past year